Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
45 hedge funds and large institutions have $384M invested in Adaptimmune Therapeutics in 2015 Q2 according to their latest regulatory filings, with 45 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
13.41% more ownership
Funds ownership: 0% → 13.41% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$106M |
| 2 |
O
OrbiMed
New York
|
+$75.7M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$30.2M |
| 4 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
+$30.2M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$18.8M |
Top Sellers
ADAP Hedge Fund Activity: Q2 2015 in Review
45 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q2 2015, worth a combined $384M.
Buyers outnumbered sellers: 45 funds opened new ADAP positions and 0 closed out — a net gain of 45 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $106M.
- 45 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $384M of Adaptimmune Therapeutics stock for Q2 2015.
- 45 funds opened new Adaptimmune Therapeutics positions in Q2 2015 and 0 closed out, a net change of +45 holders.
- The largest Adaptimmune Therapeutics buyer in Q2 2015 was Fidelity Investments, an estimated $106M added.
Based on aggregated 13F filings for Q2 2015.